Bliss GVS Pharma
Bliss GVS Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Bliss GVS Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Bliss GVS Pharma Ltd trades at a P/E of 40.18× and P/B of 4.50×.
Valuation
Profitability
Growth
Financial Health
Bliss GVS Pharma Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Bliss GVS Pharma Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Bliss GVS Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Bliss GVS Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
Bliss GVS Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹5,141.34 Cr and reported EPS of ₹12.02.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 258 | 898 | 689 | 577 | 747 | 752 | 770 | 810 | 927 |
| Other Income | -7 | 38 | 37 | 20 | 31 | 18 | 29 | 36 | 74 |
| Total Income | 252 | 936 | 726 | 597 | 779 | 769 | 799 | 846 | 1,001 |
| Cost of Goods Sold (COGS) | 95 | 612 | 440 | 329 | 391 | 401 | 382 | 414 | 425 |
| Gross Profit | 164 | 286 | 249 | 248 | 356 | 350 | 388 | 396 | 502 |
| +Operating Expenses | 88 | 128 | 126 | 142 | 238 | 233 | 238 | 269 | 338 |
| EBITDA | 76 | 158 | 123 | 107 | 118 | 117 | 151 | 127 | 164 |
| +Non-Operating Expenses | 9 | 13 | 5 | 23 | -52 | 29 | 4 | 38 | 43 |
| Profit Before Tax (PBT) | 60 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 190 |
| +Tax Expense | 18 | 55 | 34 | 30 | 31 | 29 | 35 | 35 | 55 |
| Profit After Tax (PAT) | 43 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 |
| Earnings Per Share (EPS) | 3.21 | 12.96 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 12.21 |
| Diluted Shares Outstanding (Nos.) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
| +Additional Disclosures | 282 | 1,367 | 1,026 | 828 | 1,043 | 1,064 | 1,046 | 1,138 | 1,241 |
| Sales Growth % | — | 247.65 | -23.26 | -16.26 | 29.50 | 0.55 | 2.48 | 5.13 | 14.50 |
| YoY Sales Growth % | — | 247.65 | -23.26 | -16.26 | 29.50 | 0.55 | 2.48 | 5.13 | 14.50 |
| Material Cost % | 32 | 24 | 37 | 45 | 52 | 44 | 44 | 46 | 42 |
| Employee Cost % | 8 | 5 | 8 | 12 | 10 | 11 | 12 | 14 | 15 |
| Other Cost % | 26 | 10 | 11 | 13 | 22 | 20 | 18 | 19 | 22 |
| OPM % | 29 | 18 | 18 | 18 | 16 | 16 | 20 | 16 | 18 |
| Tax % | 29 | 30 | 26 | 29 | 57 | 28 | 30 | 28 | 29 |
| Profit Growth % | — | 197.33 | -24.80 | -22.34 | -68.74 | 231.80 | 6.31 | 10.64 | 49.27 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 75 | 149 | 111 | 89 | 101 | 99 | 124 | 97 | 131 |
Bliss GVS Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Bliss GVS Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Bliss GVS Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Bliss GVS Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Bliss GVS Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Bliss GVS Pharma Ltd's investment case rests on 9 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Quarterly profit growth of 108% indicates strong recent performance.
Healthy operating profit margin of 12.35% reflects operational efficiency.
Very low debt-to-equity ratio of 0.08 signifies sound financial health.
Attractive PEG ratio of 0.22 suggests potential undervaluation relative to growth.
Diversified product portfolio across wide therapeutic areas enhances market reach.
What can break it.
Promoter holding is relatively low at 35.4%, raising governance concerns.
Significant historical volatility in profitability and stock price observed.
FII holdings declined from 17.17% to 12.65% over three years.
Low Return on Equity (ROE) of 3.86% indicates inefficient capital utilization.
Negative 5-year EPS growth of -3.37% shows long-term earnings struggle.
What would change my mind.
Trim if P/E re-rates above 52. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 2.27. Balance sheet risk re-prices growth multiples fast.
Income thesis breaks if the dividend is cut or yield falls below 0.11%.
Bliss GVS Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Bliss GVS Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Bliss GVS Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Bliss GVS Pharma Ltd — derived from the live tape, not yesterday's close.
Bliss GVS Pharma Ltd last traded at ₹486.3 with an intraday range of ₹476–₹493.75 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹486.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 530.20 | +43.90 | +9.03% |
| R3 | 512.45 | +26.15 | +5.38% |
| R2 | 503.10 | +16.80 | +3.45% |
| R1 | 494.70 | +8.40 | +1.73% |
| PIVOT | 485.35 | -0.95 | -0.20% |
| CURRENT | 486.30 | — | — |
| S1 | 441.45 | -44.85 | -9.22% |
| S2 | 459.20 | -27.10 | -5.57% |
| S3 | 467.60 | -18.70 | -3.85% |
| S4 | 476.95 | -9.35 | -1.92% |
BLISSGVS is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 476 ~ 485.95
Trading Above opening range, showing Bullishness
Bliss GVS Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Bliss GVS Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Bliss GVS Pharma Ltd stood at 43.6% of traded volume, against a 20-day average of 39.2%.
Bliss GVS Pharma announcements: results, concalls, ratings, M&A.
Filings Bliss GVS Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Bliss GVS Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 77 documents below.
Public Announcement-Open Offer
SBI Capital Markets Limited has Submitted to the Exchange a copy of newspaper publication regarding the Detailed Public Statement in connection with…
Public Announcement-Open Offer
SBI Capital Markets Limited (Manager to the Open Offer) has submitted to the Exchange a copy of Detailed Public Statement in terms of Regulation…
Updates
Bliss GVS Pharma Limited has informed the Exchange regarding 'Annual Secretarial Compliance Report for the year ended March 31, 2026'.
Public Announcement-Open Offer
SBI Capital Markets Limited (Manager to the Offer) has submitted to the Exchange a copy of Public Announcement for the attention of the Public…
Copy of Newspaper Publication
Bliss GVS Pharma Limited has informed the Exchange about Copy of the newspaper publication regarding the dispatch of the Postal Ballot Notice and…
Investor decks & rating reports.
Bliss GVS Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Bliss GVS Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Bliss GVS Pharma insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Mr. Gagan Harsh Sharma | Insider | 10 Jun 2025 | buy | +2.0 K | ₹2.69 L | ₹136.73 |
| Mr. Gagan Harsh Sharma | Insider | 09 Jun 2025 | buy | +46.7 K | ₹63.78 L | ₹136.70 |
| Mr. Gagan Harsh Sharma | Insider | 22 May 2025 | buy | +4.7 K | ₹5.72 L | ₹121.48 |
| Mr. Gagan Harsh Sharma | Insider | 21 May 2025 | buy | +37.3 K | ₹45.16 L | ₹121.20 |
| Mr. Gagan Harsh Sharma | Insider | 20 May 2025 | buy | +41.6 K | ₹50.54 L | ₹121.47 |
| Mrs. Vibha Gagan Sharma | Insider | 21 Mar 2025 | buy | +25.0 K | ₹30.66 L | ₹122.63 |
| Mrs. Vibha Gagan Sharma | Insider | 20 Mar 2025 | buy | +75.0 K | ₹90.47 L | ₹120.63 |
| Mr. Narsimha Shibroor Kamath | Insider | 19 Feb 2025 | buy | +23.0 K | ₹30.73 L | ₹133.59 |
| Mr. Narsimha Shibroor Kamath | Insider | 18 Feb 2025 | buy | +77.0 K | ₹98.19 L | ₹127.52 |
Bliss GVS Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Bliss GVS Pharma has declared, sequenced by announce and record date.
Bliss GVS Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Bliss GVS Pharma Ltd: business, sector, key facts.
What Bliss GVS Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Bliss GVS Pharma Ltd operates in the Healthcare, listed as NSE: BLISSGVS, BSE: 506197.
Bliss GVS Pharma Limited is a pharmaceutical company headquartered in Mumbai, India, established in 1984. Their core business centers around the development, manufacture, and marketing of a diverse range of pharmaceutical formulations both domestically within India and internationally through exports.
The company's product portfolio is extensive and encompasses a wide spectrum of dosage forms. This includes capsules, tablets (including effervescent), injections, suspensions, liquids, creams, ointments, gels, eye and ear drops, suppositories, pessaries, transdermal patches, and other topical preparations like lotions, balms, and sprays. They also produce various other healthcare products such as soaps, shampoos, nasal inhalers, and personal care items.
Bliss GVS's therapeutic areas covered are equally broad, reflecting their commitment to providing a comprehensive range of medications. Their offerings include products addressing pain relief (analgesics), digestive issues (antacids, anti-diarrheals, anti-emetics), infections (antibacterials, antifungals, anti-infectives), respiratory ailments (cough syrups, nasal decongestants), cardiovascular conditions, and many other therapeutic categories. This spans anti-diabetic, anti-inflammatory, anti-malarial, anti-helminthic and numerous other therapeutic areas, along with products for specific conditions such as erectile dysfunction, laryngitis, and pharyngitis. Furthermore, they offer health supplements, vitamins, and other over-the-counter (OTC) products.
In addition to their core pharmaceutical offerings, Bliss GVS expands into related health and personal care areas. They provide products like health and nutritional supplements, vitamin supplements, amino acid preparations, iron tonics, insect repellants, moisturizers, and vaginal hygiene products. This diversification demonstrates a strategy to cater to a wider consumer base beyond prescription medications.
Questions investors ask about Bliss GVS Pharma Ltd (BLISSGVS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Bliss GVS Pharma Ltd (BLISSGVS)?
The current share price of Bliss GVS Pharma Ltd (BLISSGVS) is ₹486.3. Today, the stock has gained by ₹3.35 (0.69%), trading in a range of ₹476 to ₹493.75. The stock opened at ₹478.95 with a trading volume of 9,87,034 shares.
02Is Bliss GVS Pharma Ltd stock a good investment for long-term?
Bliss GVS Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,141.34 crores, P/E ratio of 40.18, ROE of 0.00%, and ROCE of 11.70%. The dividend yield stands at 0.22%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Bliss GVS Pharma Ltd stock?
The 52-week high price of Bliss GVS Pharma Ltd (BLISSGVS) is ₹486, while the 52-week low is ₹118. Currently trading at ₹486.3, the stock is 100.1% away from its 52-week low and -0.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Bliss GVS Pharma Ltd stock at the current price?
Whether to buy Bliss GVS Pharma Ltd stock at ₹486.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 40.18 and P/B ratio of 4.50. Today's performance shows a gain of 0.69%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Bliss GVS Pharma Ltd and when is the next dividend?
Bliss GVS Pharma Ltd offers a dividend yield of 0.22%, which means for every ₹100 invested at the current price of ₹486.3, you can expect to receive approximately ₹0.22 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's key financial metrics include: P/E Ratio: 40.18, P/B Ratio: 4.50, ROE: 0.00%, ROCE: 11.70%, Dividend Yield: 0.22%, EPS: ₹12.02, Book Value: ₹107.21, and Debt-to-Equity: 1.77. The company's market cap stands at ₹5,141.34 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Bliss GVS Pharma Ltd stock performing today in the market?
Bliss GVS Pharma Ltd stock opened at ₹478.95 and is currently trading at ₹486.3, showing a gain of ₹3.35 (0.69%). The intraday high is ₹493.75 and low is ₹476. The trading volume stands at 9,87,034 shares, indicating moderate market participation today.
08What is the P/E ratio of Bliss GVS Pharma Ltd and what does it indicate?
Bliss GVS Pharma Ltd has a Price-to-Earnings (P/E) ratio of 40.18, which means investors are willing to pay ₹40.18 for every ₹1 of earnings. With an EPS of ₹12.02, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Bliss GVS Pharma Ltd (BLISSGVS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy